ARCHIVES

Pfizer’s Withdrawal Of Mylotarg Signals Stronger FDA Resolve To Monitor Confirmatory Studies

This article is from The Cancer Letter archive.

Vol. 36 No. 24 | June 25, 2010

Download PDF Visit The Full Archive

Related Articles

DCT Board Approves $8 Million In Contract Projects For Recompetition

October 31, 1980

Frederick RFP Held Up; NCI Probably Will Reject Any Further Delay

October 15, 1976

In Brief: NCI Grants Up Fourfold Since 1970; Rappaport, Jensen Speakers At Annual AACR,ASCO Meeting

April 25, 1975

Doctor’s Allegation Of Drug Safety Problem Starts Controversy With Manufacturer

May 5, 1995

Prevention, Centers To Gain, some $$ In President’s Budget

February 8, 1991

Cancer Society, With Level Budget, Cuts On More Money to Fund “Pay Ifs” In FY92

March 27, 1992